AXSM vs CYTK: stock comparison and AI forecast
Axsome Therapeutics, Inc. (AXSM) and Cytokinetics Inc (CYTK) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AXSM Axsome Therapeutics, Inc.
- Price
- $132.37 -39.9% · 6M
- Market Cap
- $6.93B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
CYTK Cytokinetics Inc
- Price
- $53.69 -27.7% · 6M
- Market Cap
- $7.46B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- AXSM and CYTK have similar market capitalizations ($6.93B and $7.46B).
- Over the last six months CYTK returned -27.7% and AXSM -39.9%.
- AXSM turns -18.2% of its revenue into net income, against -946.7% for CYTK.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AXSM | CYTK |
|---|---|---|
| Market Cap | $6.93B | $7.46B |
| P/B Ratio | 65.76x | – |
| EPS | $-3.05 | $-6.05 |
| Book Value/Share | $2.01 | – |
| Revenue/Share | $16.52 | $0.83 |
| FCF/Share | $-1.58 | $-4.23 |
Profitability & Margins
| Metric | AXSM | CYTK |
|---|---|---|
| ROE | -149.2% | – |
| ROA | -19.0% | – |
| ROIC | -47.6% | – |
| Gross Margin | 93.2% | – |
| Operating Margin | -17.4% | -915.8% |
| Net Margin | -18.2% | -946.7% |
| EBT Margin | -18.1% | -915.8% |
| Tax Rate | -0.4% | – |
Financial Health
| Metric | AXSM | CYTK |
|---|---|---|
| Current Ratio | 1.42x | 3.36x |
| Quick Ratio | 1.34x | 3.36x |
| D/E Ratio | 6.84x | – |
| Financial Leverage | 7.84x | – |
| Interest Coverage | 3.2x | -13.3x |
| Working Capital | $215M | $834M |
Cash Flow
| Metric | AXSM | CYTK |
|---|---|---|
| Operating Cash Flow | -$82M | -$572M |
| Free Cash Flow | -$83M | -$589M |
| Capital Spending | -$840K | -$17M |
| FCF/Sales | -9.6% | -512.4% |
| CapEx/Sales | 0.1% | 14.5% |
Operational Efficiency
| Metric | AXSM | CYTK |
|---|---|---|
| Asset Turnover | 1.05x | – |
| Receivables Turnover | 2.5x | 3.4x |
| Inventory Turnover | 1.4x | – |
| Fixed Assets Turnover | 917.6x | 1.5x |
| Days Sales Outstanding | 145 days | 108 days |
| Days Inventory | 266 days | – |
| Payables Period | 600 days | – |
| Cash Conversion Cycle | -189 days | – |
Income Statement
| Metric | AXSM | CYTK |
|---|---|---|
| Total Revenue | $865M | $115M |
| Operating Income | -$151M | -$708M |
| Net Income | -$157M | -$732M |
| R&D Expense | $198M | $397M |
| SG&A Expense | $766M | – |
| Cost of Goods Sold | $58M | – |
Dividend & Shareholder Information
| Metric | AXSM | CYTK |
|---|---|---|
| Shares Outstanding | 52M | 139M |
AXSM vs CYTK: stock comparison and AI forecast
Which is bigger, AXSM or CYTK?
AXSM and CYTK have similar market capitalizations ($6.93B and $7.46B).
Which stock performed better over the last six months, AXSM or CYTK?
Over the last six months CYTK returned -27.7% and AXSM -39.9%.
Which one does Intratio's AI model rank higher, AXSM or CYTK?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.